glp-1 drugs market dynamics 2025 Receptor Agonist Size GLP-1 Receptor Agonists Obesity Drugs
Description
Phone-only cancellation with a retention script
They, too, benefit from FDA approval protecting their brand from competition
As previously noted, PIONEER 4 is an important trial that compared the novel oral GLP-1 receptor agonist product against the market-leader injectable GLP-1 receptor agonist product, liraglutide
Both trials enrolled predominantly high-risk populations81% of LEADER and 83% of SUSTAIN-6 participants had established cardiovascular disease [3]
revenue since 2018, with Ozempic alone accounting for roughly half of that total [38]
Obesity StatPearls
